Organisms respond to a variety of environmental agents, such as those that cause inflammation, by mounting a coordinated complex series of adaptive responses involving the immune, nervous and endocrine systems. These adaptations are aimed at restoring the homeostatic balance and the return to the status quo ante. This interaction is facilitated by cytokines, hormones and neurotransmitters, as well as receptors that are endogenous to the neural, immune and endocrine systems. These shared ligands and receptors provide the molecular basis of this cross-talk. Studies of animal models of autoimmune diseases have shown that defects in the neuroendocrine immune communications contribute to the development of chronic inflammatory autoimmune disease. By analogy, similar observations have now been made in patients with inflammatory rheumatic disorders. For instance, patients with rheumatoid arthritis have abnormally low cortisol responses to inflammation, whilst the production of prolactin is excessive and dysregulated. Prolactin is a pro-inflammatory neuropeptide. This paper reviews the evidence to support the viewpoint that the neuropeptide arginine vasopressin, which is also produced by the hypothalamus, should be considered to be another neuroendocrine modulator of immune and inflammatory responses. It is also being hypothesized that the production of arginine vasopressin might be dysregulated and excessive in rheumatoid arthritis, and that this could be another additional neuroendocrine factor contributing to the pathophysiology of the disease. The release of the pro-inflammatory and antiby the liver as part of the systemic response to inflaminflammatory cytokines [13, 14] is associated with the mation [3, 4], these cytokines also trigger a cascade of local production of CRH, prolactin and substance P neuroendocrine mechanisms that regulate the body's [15][16][17]. CRH is pro-inflammatory within the microresponse and the eventual termination of inflammation environment where immune reactions are occurring by three major pathways [4]. The first mechanism is [15]. Substance P potentiates the pain response and the activation of the sympathetic nervous system to augments T-cell activation by enhancing IL-2 producincrease catecholamine and bradykinin release which tion [18]. During normal physiological function, enhance corticosteroid release by adrenal glands [4, 5].
T immune, endocrine and nervous systems are highly with arginine vasopressin (AVP) to induce the release of ACTH, which in turn stimulates the production of integrated, orchestrate the interaction of the organism corticosteroids by the adrenal glands [9] (Fig. 1) . with the environment, and exhibit memory as well as Corticosteroids dampen the inflammatory response by exerting various effects on different types of cells.
inhibiting cytokine production [4] . The pituitary gland Inflammatory cytokines, in particular interleukin-1b also releases prolactin, b-endorphin, melanocyte-(IL-1b), tumour necrosis factor-a ( TNF-a) and IL-6, stimulating hormones (a-MSH ) and other neuropepreleased in inflammatory sites such as joints, activate tides that act on the gonadal and thyroid glands [4, inflammatory cells such as monocytes, macrophages 10]. Prolactin has potent pro-inflammatory functions and T cells via autocrine and paracrine mechanisms [11] , whilst a-MSH is anti-inflammatory and downreg-[1] and, by upregulating adhesion molecule expression ulates the fever response as well as the inflammatory [2] , facilitate the local accumulation of inflammatory effects of IL-1b [12] . cells. In addition to initiating the acute-phase response
The release of the pro-inflammatory and antiby the liver as part of the systemic response to inflaminflammatory cytokines [13, 14] is associated with the mation [3, 4] , these cytokines also trigger a cascade of local production of CRH, prolactin and substance P neuroendocrine mechanisms that regulate the body's [15] [16] [17] . CRH is pro-inflammatory within the microresponse and the eventual termination of inflammation environment where immune reactions are occurring by three major pathways [4] . The first mechanism is [15] . Substance P potentiates the pain response and the activation of the sympathetic nervous system to augments T-cell activation by enhancing IL-2 producincrease catecholamine and bradykinin release which tion [18] . During normal physiological function, enhance corticosteroid release by adrenal glands [4, 5] .
immune and inflammatory responses are modulated The second involves the generation of fever and the by the circadian rhythm of secretion of corticosteroids adoption of adaptive behaviour conducive to recovery and prolactin determined by a periodic clock in the [6, 7] . Finally, a variety of neuropeptides that are hypothalamus [19] . The changes in these hormones involved in the stress response, including corticoover 24 h produce measurable variations in immune trophin release hormone (CRH ), adrenocorticotrophic function [20, 21] immune inflammatory disorders [23, 24] . Female Lewis production [24, 34] . The latter observation is also found in patients with systemic lupus erythematosus (LEW/N ) rats develop streptococcal cell wall peptidoglycan (SCW )-induced chronic arthritis [25] and (SLE), Reiter's and primary Sjögren's syndromes [35] [36] [37] . Prolactin is an important pro-inflammatory experimental allergic encephalomyelitis [26 ] , whilst the obese strain of chicken develops spontaneous autoneuropeptide [11] . AVP production, like that of corticosteroids and immune thyroiditis [26 ] . The susceptibility to developing chronic inflammatory diseases in Lewis rats, and prolactin, has a diurnal rhythm of secretion with a peak in the morning [38] . It is also involved in the to developing autoimmune thyroiditis in the obese strain of chicken, is directly linked to an inability to exercise-induced stress response [39] . This paper reviews the evidence to support the viewpoint that mount an adequate ACTH and corticosteroid response at the onset of inflammation [27] [28] [29] . This defect in AVP should be considered to be another neuroendocrine hormone which exerts direct effects on immune Lewis rats is also be seen following injections of inflammatory cytokines such as IL-1a, and hypothaland inflammatory responses. It is also proposed that its production is dysregulated in patients with RA and amic stimulants such as serotonin and quipazine. The histocompatible Fisher rats ( F344/N ) only develop that this could be another additional contributory neuroendocrine factor in the pathophysiology of the acute transient polyarthritis, and mount a normal ACTH and corticosterone response [25, 28] .
disease. What is the relevance of these observations to human THE REGULATION OF ARGININE chronic autoimmune inflammatory disease? In humans, VASOPRESSIN SECRETION increased mortality to septicaemia is linked to defective cortisol responses to Gram-negative infections [30] .
AVP is a nonapeptide produced by the magnocellular and parvicellular neurones of the paraventricular nucPatients with rheumatoid arthritis (RA) have defective hypothalamo-pituitary-adrenal axis responses to leus (PVN ) of the hypothalamus, as well as the magnocellular neurones of the supraoptic nucleus (SON ) inflammation characterized by inappropriately low levels of circulating cortisol for the degree of joint [40] [41] [42] . The parvicellular neurones secrete both AVP and CRH into the median eminence where both pepinflammation [23, 24, [31] [32] [33] and excessive prolactin tides are transported via the hypophyseal portal vessels susceptible to developing severe chronic inflammatory diseases, whereas the histocompatible Fischer rats to the pituitary [9] . SON cells have glucocorticosteroid receptors, whilst the PVN magnocellular AVP neurones (F344/N ) are resistant [25] . The Lewis rats also have a significantly high plasma concentration, hypothalappear not to, suggesting a direct modulation only of SON AVP neurones by corticosteroids [43, 44] . amic content and in vitro release of AVP (and not oxytocin) in comparison with the F344/N rats [63, 64] . Magnocellular AVP reaches the hypophyseal portal system via the fenestrated capillaries of the subependyIt is possible that these findings might represent a compensatory adaptation to deficient CRH and mal plexus and the anterior pituitary via the vascular connections between the two lobes [45] .
corticosterone secretion. Since systemic immunoneutralization of AVP in Lewis rats attenuates inflammatThe release of AVP from the posterior pituitary is controlled by osmoreceptor cells situated in the ory responses, the high levels of circulating AVP are therefore an additional neuroendocrine factor contribanterior hypothalamus and the organosum vasculosum of the lamina terminalis [10] . Other stimuli include uting to the susceptibility to developing chronic inflammatory disease [65, 66 ] . The low levels of hypotension, acute stress, morphine, nicotine, carbamazepine, chlorpromazine, hypoglycaemia and angiocorticosterone and high levels of circulating AVP would favour the development of a predominantly Th 1 cellutensin II, whilst alcohol inhibits secretion [10] . Endothelins and atrial natriuretic peptide increase and lar response and the generation of arthritogenic T cells [67] . decrease AVP secretion, respectively, in rats, but this remains to be determined in man [46, 47] .
The effects of IL-1b, TNF-a and IL-6 on the magnocellular AVP system are not fully characterized [4, 68, The gene for AVP in man is on chromosome 20p13, whilst in mice it is on chromosome 2 which also carries 69]. However, most studies in rats suggest a stimulatory effect of IL-1b on AVP secretion [70- infusions of substance P increase serum levels of AVP in a dose-dependent manner whilst inhibiting ACTH These effects are mediated via V 1 , V 2 and V 3 receptors that show a differential tissue distribution [54] [55] [56] [57] .
release [75, 76 ] . Since there is evidence that AVP is pro-inflammatory, excessive production of AVP in man This raises the possibility of selective inhibition. V 1 receptors mediate the vascular effects [54] and are may contribute to the susceptibility to developing chronic inflammation. subdivided into V 1a receptors found on hepatocytes and V 1b in the pituitary [56 ] . V 2 receptors mediate IMPLICATIONS FOR HUMAN DISEASE renal effects, whilst the putative V 3 receptors are thought to mediate the behaviour and learning funcThe evidence reviewed above shows that AVP exerts pro-inflammatory effects on immune cells. Patients tions [57] .
with [58] . This effect is dose dependent and can be blocked by V 1 receptor inhibitors ute to the chronicity of the disease. In Lewis rats, the lack of a corticosterone response to inflammation [58, 60] . AVP can replace the IL-2 requirement for interferon gamma (IFN-c) production [59, 60] . Highassociated with deficient ACTH production, but with increased production of CRH in inflamed joints and affinity V 1 receptors are found on human peripheral blood mononuclear cells and splenic lymphocytes [61, high levels of plasma AVP, contributes to the susceptibility to the development of inflammatory disease [25, 62] . Thus, the existence of these receptors on inflammatory cells suggests that AVP has potential immuno- 28, 63, 66 ] . A pro-inflammatory role for AVP in the neuroendocrine immunopathophysiology of inflammodulatory properties. In experimental animals, AVP potentiates primary antibody responses in vivo [53] . matory disease in Lewis rats is supported by the fact that systemic immunoneutralization of AVP attenuates As reviewed above, Lewis (LEW/N ) rats are highly inflammatory responses [65] . Invoking direct human A implications might be premature at the moment. CRH We would like to thank Professor D. R. Blake for is pro-inflammatory and is produced in the joints of reviewing this manuscript and for making constructive RA patients, where it might potentiate inflammation suggestions. [77] . It can be hypothesized that its functional companion AVP might be secreted into joints in a similar R manner or, if present in excessive levels in the circula- AVP production in Lewis rats is a susceptibility factor 
